Scholarlink

<p>Identifying precise molecular targets is hindered by intricate disease mechanisms and the necessity for specificity. Biological noise and emerging resistance mechanisms demand personalized and combination therapies. Artificial intelligence (AI) holds promise for improving drug design by analyzing large omics datasets to pinpoint relevant targets, reducing drug candidate failures, and expediting preclinical testing through in silico methods. However, challenges include biological complexity, feature selection, data quality, and model interpretability. Despite advances in AI for drug screening and target identification, enhancing molecular-level drug responses is a significant challenge. Biological noise, gene expression fluctuations, and cellular dynamics are vital considerations for bioengineering. This paper tackles current drug development challenges, emphasizing the role of biological noise at the molecular level. We describe noise-related challenges in structure-based drug design and highlight the need to account for protein and ligand flexibility in molecular docking and molecular dynamics simulations. Molecular mechanics and genetic algorithms are also explored as strategies to optimize drug binding. The constrained disorder principle (CDP)-based second-generation AI platform is being developed for drug development. The paper provides a perspective on how the CDP-based AI platform can address challenges at the pre-target, target, and post-target levels. It suggests techniques to incorporate variability into drug design and administration, ultimately leading to more effective and personalized therapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Improving drug effectiveness using a second-generation artificial intelligence system based on the constrained-disorder principle to incorporate variability into drug design and administration: a perspective

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月10日

查看全文
  • Noa Hurvits,
  • Adi Holander,
  • Adir Israeli,
  • Tal Sigawi,
  • Yaron Ilan

摘要

Identifying precise molecular targets is hindered by intricate disease mechanisms and the necessity for specificity. Biological noise and emerging resistance mechanisms demand personalized and combination therapies. Artificial intelligence (AI) holds promise for improving drug design by analyzing large omics datasets to pinpoint relevant targets, reducing drug candidate failures, and expediting preclinical testing through in silico methods. However, challenges include biological complexity, feature selection, data quality, and model interpretability. Despite advances in AI for drug screening and target identification, enhancing molecular-level drug responses is a significant challenge. Biological noise, gene expression fluctuations, and cellular dynamics are vital considerations for bioengineering. This paper tackles current drug development challenges, emphasizing the role of biological noise at the molecular level. We describe noise-related challenges in structure-based drug design and highlight the need to account for protein and ligand flexibility in molecular docking and molecular dynamics simulations. Molecular mechanics and genetic algorithms are also explored as strategies to optimize drug binding. The constrained disorder principle (CDP)-based second-generation AI platform is being developed for drug development. The paper provides a perspective on how the CDP-based AI platform can address challenges at the pre-target, target, and post-target levels. It suggests techniques to incorporate variability into drug design and administration, ultimately leading to more effective and personalized therapeutic strategies.